版本:
中国

BRIEF-Glenmark Pharmaceuticals initiates clinical investigation for GBR 310, proposed biosimilar candidate for XOLAIR

April 25 Glenmark Pharmaceuticals Ltd:

* Glenmark Pharmaceuticals initiates clinical investigation for GBR 310, its proposed biosimilar candidate for Xolair® Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐